A phase I, dose escalation and pharmacokinetics study of temperature sensitive liposome encapsulated doxorubicin (ThermoDox) and hyperthermia in patients with local-regionally recurrent breast cancer.

Trial Profile

A phase I, dose escalation and pharmacokinetics study of temperature sensitive liposome encapsulated doxorubicin (ThermoDox) and hyperthermia in patients with local-regionally recurrent breast cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs Doxorubicin liposomal (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Sep 2014 Results published in the Media Release.
    • 09 Sep 2013 Results have been presented at the 2013 San Antonio Breast Cancer Conference according to a Celsion Corporation media release.
    • 27 Apr 2009 According to a Celsion media release, 16 patients have been treated to date with ThermoDox at doses ranging from 20-40 mg/m2.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top